UNION therapeutics announces two peer-reviewed publications of preclinical and clinical Phase 2a data on orismilast
New insights into the pharmacological properties of orismilast and Phase 2a data published in peer-reviewed journal JEADV Data supports orismilast’s potential as a first-in-class or best-in-class treatment for a range […]
UNION therapeutics to present at the Dermatology Summit 2023
UNION invited to present orismilast at the Dermatology Summit 2023 Orismilast is a potent next-generation PDE4 inhibitor with broad anti-inflammatory properties in development as a first-in-class or best-in-class treatment for […]
UNION therapeutics and Innovent announce first subject dosed in a Chinese clinical Phase 1 study of orismilast, a novel PDE-4 inhibitor
Hellerup, Denmark and ROCKVILLE, M.D., Suzhou, China, 5 December 2022 – UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases, and Innovent […]
UNION therapeutics completes 62 million DKK private placement to support clinical program
Hellerup, Denmark, 1 December 2022 – UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases, today announced the completion of a […]
UNION therapeutics to present at the 6th Annual Dermatology Drug Development Summit
Data on pharmacological properties of orismilast to be presented on 2nd of November 2022 Orismilast is a potent next-generation PDE4 inhibitor with broad anti-inflammatory properties in development as a first-in-class […]
UNION therapeutics presents new data on orismilast at the 31st EADV Congress supporting orismilast’s potential as a first-in-class or best-in-class treatment for certain immunological diseases
Preclinical data presented in the oral presentation demonstrate that orismilast is a potent inhibitor of phosphodiesterase type-4 (PDE4), and that orismilast more selectively inhibit PDE4B and PDE4D subtypes which are […]
UNION therapeutics announces regulatory approval of Treatment Extension for the ongoing OSIRIS Phase 2a open label study with orismilast MR tablet for patients with Hidradenitis Suppurativa (HS)
OSIRIS is an investigator-initiated Phase 2a open label study, studying orismilast modified release (MR) tablet as a potential treatment for HS Treatment Extension gives the possibility to allow patients to […]
UNION therapeutics announces presentation of new data on orismilast at the 31st EADV Congress
Oral presentation of new preclinical data on pharmacological properties of orismilast at the EADV Congress Additional e-poster details the safety and efficacy of orismilast IR (immediate release) tablets in adults […]
UNION therapeutics completes patient enrollment in the IASOS Phase 2b study of orismilast MR tablet in patients with psoriasis
Topline results expected in first half of 2023 Orismilast is a potent next generation PDE4 inhibitor with broad anti-inflammatory properties also in development for the treatment of hidradenitis suppurativa (HS) […]
UNION therapeutics announces enrollment of the first patient in ADESOS Phase 2b study of orismilast MR tablet in patients with atopic dermatitis
ADESOS is a Phase 2b dose-finding study of orismilast modified release (MR) tablet in moderate to severe atopic dermatitis (AD) with the purpose of identifying the appropriate dose-regimen for Phase […]